Here is the full list of the biotech and pharma Startup Battlefield 200 selectees, along with a note on what made us select ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...

Something remarkable is happening in Chinese biotech, and it’s happening fast. The country’s drug developers are learning to ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

Biotech Showcase™ returns to San Francisco during J.P. Morgan Healthcare Week, marking its 19 th year as a premier destination for global biopharma leaders to showcase their companies and technologies ...